High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: A single centre 10-year experience

Multiple Sclerosis

Volumn 16, Issue 6, 2010, Pages 685-693

  Krasulová, Eva ^a   Trněný, Marek ^a   Kozák, Tomáš ^b   Vacková, Blanka ^a   Pohlreich, David ^a   Kemlink, David ^a   Kobylka, Petr ^c   Kovářová, Ivana ^a   Lhotáková, Petra ^b   Havrdová, Eva ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Aggressive; Immunoablation; Immunosuppression; Multiple sclerosis; Stem cell transplantation; Survival

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GLATIRAMER; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; MELPHALAN; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; ANTINEOPLASTIC AGENT;

ADULT; ARTHRALGIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHICKENPOX; CLINICAL ARTICLE; CLINICAL EVALUATION; DIARRHEA; DISEASE COURSE; DISEASE DURATION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GLIOBLASTOMA; HEPATITIS B; HERPES VIRUS INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MALE; MUCOSA INFLAMMATION; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; RATING SCALE; RELAPSE; SEPSIS; SIDE EFFECT; STEM CELL MOBILIZATION; THERAPY EFFECT; TREATMENT DURATION; URINARY TRACT INFECTION; AGE; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; MULTIMODALITY CANCER THERAPY; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; KAPLAN-MEIER ESTIMATE; MALE; MELPHALAN; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 77953735863     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510364538     Document Type: Article

References (36)

1. Compston A, McDonald I, Noseworthy J, et al (eds) McAlpines multiple sclerosis, 4 th edn. Edinburgh: Elsevier Churchill Livingstone, 2006.
2. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004 ; 14: 164-174.
3. Hofstetter H., Gold R., Hartung HP Th17 cells in MS and experimental autoimmune encephalomyelitis. Int MS J 2009 ; 16: 12-18.
4. Medana I., Martinic MA, Wekerle H., Neumann H. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 2001 ; 159: 809-815.
5. van Bekkum DW Stem cell transplantation for autoimmune disorders. Preclinical experiments. Best Pract Res Clin Haematol 2004 ; 17: 201-222.
6. Karussis DM, Slavin S., Lehmann D., Mizrachi-Koll R., Abramsky O., Ben-Nun A. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J Immunol 1992 ; 148: 1693-1698.
7. Karussis DM, Slavin S., Ben-Nun A., et al. Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation. J Neuroimmunol 1992 ; 39: 201-210.
8. van Gelder M., Kinwel-Bohre EP, van Bekkum DW Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT. Bone Marrow Transplant 1993 ; 11: 233-241.
9. Burt RK, Padilla J., Begolka WS, Canto MC, Miller SD Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis. Blood 1998 ; 91: 2609-2616.
10. Ikehara S., Good RA, Nakamura T., et al. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci USA 1985 ; 82: 2483-2487.
11. Snowden JA, Patton WN, ODonnell JL, Hannah EE, Hart DN Prolonged remission of longstanding systemic lupus erythematosus after autologous bone marrow transplant for non-Hodgkins lymphoma. Bone Marrow Transplant 1997 ; 19: 1247-1250.
12. McAllister LD, Beatty PG, Rose J. Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant 1997 ; 19: 395-397.
13. Fassas A., Anagnostopoulos A., Kazis A., et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997 ; 20: 631-638.
14. Su L., Xu J., Ji BX, et al. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int J Hematol 2006 ; 84: 276-281.
15. Fassas A., Anagnostopoulos A., Kazis A., et al. Autologous stem cell transplantation in progressive multiple sclerosis-an interim analysis of efficacy. J Clin Immunol 2000 ; 20: 24-30.
16. Kozak T., Havrdova E., Pitha J., et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000 ; 25: 525-531.
17. Shevchenko YL, Novik AA, Kuznetsov AN, et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol 2008 ; 36: 922-928.
18. Samijn JP, te Boekhorst PA, Mondria T., et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry 2006 ; 77: 46-50.
19. Carreras E., Saiz A., Marin P., et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica 2003 ; 88: 306-314.
20. Loh SM, Ratnagopal P., Tan HC, et al. Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning. Int J Hematol 2006 ; 83: 368-369.
21. Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003 ; 102: 2364-2372.
22. Gualandi F., Bruno B., Van Lint MT, et al. Autologous stem cell transplantation for severe autoimmune diseases: a 10-year experience. Ann NY Acad Sci 2007 ; 1110: 455-464.
23. Ni XS, Ouyang J., Zhu WH, Wang C., Chen B. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transplant 2006 ; 20: 485-489.
24. Poser CM, Paty DW, Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983 ; 13: 227-231.
25. Kurtzke JF Neurologic impairment in multiple sclerosis and the disability status scale. Acta Neurol Scand 1970 ; 46: 493-512.
26. Fassas A., Passweg JR, Anagnostopoulos A., et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 2002 ; 249: 1088-1097.
27. Saccardi R., Kozak T., Bocelli-Tyndall C., et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler 2006 ; 12: 814-823.
28. Mancardi G., Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008 ; 7: 626-636.
29. Burt RK, Cohen BA, Russell E., et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003 ; 102: 2373-2378.
30. Dubinsky AN, Burt RK, Martin R., Muraro PA T-cell clones persisting in the circulation after autologous hematopoietic SCT are undetectable in the peripheral CD34+ selected graft. Bone Marrow Transplant 2010 ; 45 (2). 325-331 (Epub 2009 Jun 22).
31. Havrdova E., Zivadinov R., Krasensky J., et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler 2009 ; 15: 965-976.
32. Burt RK, Marmont A., Oyama Y., et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum 2006 ; 54: 3750-3760.
33. Mancardi GL Present status of HSCT in MS. Mult Scler 2007 ; 13 (Suppl. 2). S22.
34. Huth-Kuhne A., Baudo F., Collins P., et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009 ; 94: 566-575.
35. Kaloyannidis P., Sakellari I., Fassas A., et al. Acquired hemophilia-A in a patient with multiple sclerosis treated with autologous hematopoietic stem cell transplantation and interferon beta-1a. Bone Marrow Transplant 2004 ; 34: 187-188.
36. Gratwohl A., Passweg J., Bocelli-Tyndall C., et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 2005 ; 35: 869-879. (Pubitemid 40667629)